Business
Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035
Opportunities in the adalimumab, infliximab, and etanercept biosimilars market arise from growing autoimmune disease prevalence, increased biosimilar awareness, manufacturing advancements, regulatory support, and demand for cost-effective treatments. Expansion in precision medicine and digital health adoption also fuels market potential. Adalimumab, Infliximab and Etanercept Biosimilars Market Adalimumab, Infliximab and Etanercept Biosimilars Market Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "
About this update from Abbvie Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Opportunities in the adalimumab, infliximab, and etanercept biosimilars market arise from growing autoimmune disease prevalence, increased biosimilar awareness, manufacturing advancements, regulatory support, and demand for cost-effective treatments. Expansion in precision medicine and digital health adoption also fuels market potential.","length":339,"tagName":"p"},{"type":"text","content":"Adalimumab, Infliximab and Etanercept Biosimilars Market","length":56,"tagName":"p"},{"type":"image","alt":"Adalimumab, Infliximab and Etanercept Biosimilars Market","displaySize":"","headline":null,"caption":"Adalimumab, Infliximab and Etanercept Biosimilars Market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/881b114ac4ccacb516846789e172dea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HvwiiYc79HlnqBLdXAvnLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA--/https://media.zenfs.com/en/globenewswire.com/881b114ac4ccacb516846789e172dea8","width":600,"height":400}}},{"type":"text","content":"Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026" has been added to ResearchAndMarkets.com's offering.","length":183,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/221fb1328be0f7e24250fbc7e9f24c75"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xTUkqvuvCNroahMBw8b9LA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA--/https://media.zenfs.com/en/globenewswire.com/221fb1328be0f7e24250fbc7e9f24c75","width":600,"height":400}}},{"type":"text","content":"The adalimumab, infliximab, and etanerce...